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Production of Interleukin-1 by Bone Marrow Myeloma Cells
By Federico Cozzolino, Maria Torcia, Donatella Aldinucci, Anna Rubartelli, Anna Miliani, Alan R. Shaw,
Peter M. Lansdorp, and Renato Di Guglielmo
Plasma cells isolated from bone marrow (BM) aspirates of
i2 patients with multiple myeloma (MM) and nine patients
with monoclonal gammopathy of undetermined signifi-
cance (MGUS) were analyzed for production of cytokines
with bone-resorbing activity, such as interleukin-i (IL-i).
tumor necrosis factor (TNF). and lymphotoxin (LT). Culture
supernatants of plasma cells from MM, but not from MGUS
or normal donor, invariably contained high amounts of
IL-i-fl and lower amounts of IL-i-a. With a single excep-
tion, TNF/LT biologic activity was not detected in the same
supernatants. lL-6 was present in two of five supernatants
tested. Normal B lymphocytes released both IL-i and
TNF/LT activities for four days after activation in vitro;
however, production of these cytokines ceased at the final
L YTIC BONE LESIONS are a prominent feature of
multiple myeloma (MM). Since the original descrip-
tion by Mundy et al,’ ample evidence has accumulated that
bone resorption is related to the action of factor(s) produced
by the malignant cells, termed osteoclast-activating factor
(OAF). The biochemical characterization of OAF revealed
that several different proteins can mediate this biologic
effect.2 Among these are interleukin-l (IL-l)-a, IL-I-fl,
tumor necrosis factor (TNF), and lymphotoxin (LT).3
Further studies showed that these factors interact with
osteoblasts, which are ultimately responsible for metabolic
activation of osteoclasts.7’8
In this study, we investigated production of the above
factors by freshly isolated bone marrow (BM) plasma cells
from patients with monoclonal gammopathy (MG) or nor-
mal subjects and by plasma cells generated in cultures of
peripheral blood lymphocytes (PBLs). We show that malig-
nant plasma cells invariably produce relevant amounts of
IL-I and, in a single case, TNF as well. Although MM
plasma cells expressed the genes for both TNF and LT in the
cases studied, their biologic activities were never detected in
culture supernatants. We therefore conclude that IL-I is the
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stage of plasma cell. Unexpectedly. the mRNA extracted
from MM plasma cells hybridized with TNF- and LT-
specific. as well as IL-i -specific probes, although the
culture supernatants did not contain detectable TNF/LT
biologic activity. When tested in the fetal rat long bone
assay. MM plasma cell supernatants displayed a strong
osteoclast-activating factor (OAF) activity, which was
greatly reduced but not completely abolished by neutraliz-
ing anti-IL-i antibodies. Anti-TNF or anti-LT antibodies
were ineffective in the same test. We conclude that the
IL-i released in vivo by malignant plasma cells has a major
role in pathogenesis of lytic bone lesions of human MM.
to 1989 by Grune & Stratton, Inc.
predominant factor responsible for the lytic bone lesions of
MM.
MATERIALS AND METHODS
Patients. Twenty-one patients with MG were studied, 12 with
MM and nine with MG of undetermined significance (MGUS).
Diagnosis of MM was established according to conventional crite-
na,9 and the patients were selected for the presence of lytic bone
lesions. Patients with MGUS were selected according to the stability
of their hematologic and humoral parameters for >5 years. BM
specimens were obtained, after informed consent, from needle
biopsies performed for periodic controls.
Reagents. Purified human recombinant (hr) IL-I-a and IL-I-fl
were obtained as described.’0” Both had a specific activity of 1.3 x
I0 half-maximal units per milligram in the thymocyte costimula-
tion assay. Purified hrTNF, hrLT, hrIFN--y, specific activity 9.6 x
106 and 8.9 x l0 units per milligram in the L929 cytotoxicity assay,
and 2.1 x 10 NIH reference units per milligram, respectively, were
the kind gift of Biogen S.A., Geneva, Switzerland. Neutralizing
antisera specific for IL-l-a, IL-l-fl, and TNF were obtained in
rabbits, using the recombinant proteins as immunogen. They con-
tamed l0, 0.5 x 106, and 2 x I0 neutralizing units per milliliter,
respectively. The absence of cross-reactivity of anti-IL-l-a and
anti-IL-I-fl antisera was assessed in the LAF assay, in which both
failed to affect thymocyte proliferation in response to IL- 1-fi and -a,
up to concentrations of I :50. The mouse monoclonal antibody
(MoAb) LTX-9 to human LI, tO5 neutralizing units per milligram,
was provided by Dr G. Adolf, Ernst-Boehringer-Institut f#{252}rArz-
neimittelforschung, Vienna.
The DNA probes specific for IL-I-a and IL-l-fl consisted of Eco
RI fragments from pSPhILIa.2 and pSPhIL1fl.2, recognizing the
coding regions of IL-I-a and IL-l-fl, respectively. The probes
specific for TNF and LT, provided by Dr E. Kawashima, Biogen
S.A., have been described elsewhere.’2
Isolation and culture ofcells. BM samples were diluted I : I with
Hanks’ balanced salt solution (HBSS) and mononuclear cells were
isolated by Ficoll-Hypaque (Pharmacia, Milan) density-gradient
centrifugation. Cells at the interface were resuspended in RPM!
1640 culture medium (Flow Laboratories, Milan) supplemented
with 2 mmol/L L-glutamine, 100 zg/mL streptomycin, 100 U/mL
penicillin (hereafter referred to as complete medium, CM), and 10%
heat-inactivated fetal calfserum (FCS, Flow). Normal BM samples
were obtained from patients undergoing cardiac surgery and treated
similarly. Plasma cells were purified from the above suspensions by a
direct rosetting procedure with ox RBCs coated with the MoAb
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purified from ascites fluid of mice injected with the OK 110
hybridoma clone (ATCC, American Type Culture Collection, Rock-
ville, MD) or with the AlO hybridoma clone (gift of Dr F. Malavasi,
University of Turin, Italy), as described previously.’3 Alternatively,
cells expressing the PCA- 1 were separated by the indirect rosetting
procedure as described previously.’4 Cells (2 x I0) were resus-
pended in 400 L 1 :10 dilution of PCA-l MoAb (Coulter-Kontron,
Milan) in HBSS and kept at 4#{176}Cfor 30 minutes. After two washes
with cold HBSS, cells were incubated with a 1% suspension of ox
RBCs coated with F(ab’)2 fragments of affinity-purified goat anti-
mouse Igs at 37#{176}Cfor one hour. Rosetting cells were then separated
by Ficoll-Hypaque density gradients, and RBCs were lysed by
incubating at 4#{176}Cfor ten minutes with a 0.83% NH4CI solution.
Aliquots of cells obtained by either procedure were cytocentrifuged
and examined for the percentage of plasma cells by May-Grunwald-
Giemsa staining. When necessary, the cell suspension was further
purified by a one-step complement-mediated cytotoxicity as
described previously)2 Cells (I x l0) were incubated at 4#{176}Cin 1
mL CM-FCS containing a mixture of purified OK TI 1 MoAb
(ATCC), 1:20 final dilution, Bl MoAb (Coulter-Kontron), 1:40
final dilution, and MY 4 MoAb (Coulter-Kontron), 1:20 final
dilution. After incubation on ice for 30 minutes, nontoxic rabbit
complement (PcI-Freeze, Societ#{224}Italiana Chimici, Milan), 1:2 final
dilution, was added, and the suspension was kept at 37#{176}Cfor one
hour. Dead cells were removed by centrifugation on Ficoll-Hypaque
gradients. The purity of the cell suspension was checked again by
cytoplasmic immunofluorescence analysis using FITC-conjugated
rabbit anti-human Ig antiserum. Contaminating cells were repre-
sented mainly by erythroblasts, with few lymphoid cells. Cell
suspensions containing <90% viable plasma cells were discarded.
Normal BPBLs were purified from buffy coats by an indirect
rosetting procedure using the BI MoAb. Small tonsil B lymphocytes
were obtained by depletion of I cells by double rosetting with
neuraminidase-treated sheep erythrocytes and Percoll (Pharmacia)
density-gradient fractionation as described previously.’3 The cells
were cultured at 1 x 106/mL in CM-FCS for seven days with killed
Staphylococcus aureus of the I Cowan strain (donated by Dr S.
Romagnani, University of Florence). At the end of the incubation
period, cells were harvested and centrifuged over Ficoll-Hypaque
gradients to remove cell debris. Plasma cells were isolated by the
procedures described above.
BM MNCs and purified plasma cells were cultured for 48 hours
at 37#{176}Cin a humidified atmosphere with 5% CO2 with or without hr
interferon--y (hrIFN-T), 2,000 U/mL, phytohemagglutinin (PHA,
Wellcome, Pomezia, Italy), 1 .tg/mL, or lipolysaccharide from E
coli (Sigma, St Louis), 10 jzg/mL; supernatants were harvested and
tested for IL-I, TNF/LT, and OAF activities. In some experiments,
cells were incubated for four hours in CM-FCS with cycloheximide
(cyc, Sigma), I g/mL, then washed six times and cultured as above.
For the kinetic analysis of cytokine production, normal B PBLs were
cultured in 24-well plates at 1 x 106 cells/mL. Supernatants were
harvested daily and replaced with fresh CM-FCS; aliquots of cells
were cytocentrifuged, fixed, and analyzed for intracytoplasmic Ig by
immunofluorescence as above. The RPM! 8226 myeloma cell line
was obtained from ATCC (Cat. no. 155-CCL) and cultured in
CM-FCS.
IL-i assay. IL-l activity in culture supernatants was deter-
mined as describ#{231}d previously.’5 C3H/HeJ mouse thymocytes
(1 .5 x I 06) were cultured in triplicate for 72 hours in 96-well plates,
with 1 g/mL PHA alone, or PHA plus serial dilutions of the
supernatants to be assayed. In some experiments, anti-IL-I-a or
anti-IL-I-fl antibodies, or both, were added at a final dilution of
1:500. The cells were pulsed in the last eight hours with 3H-
thymidine (3H-TdR, Amersham, Amity-PG. Milan) 0.5 MCi/well,
harvested, and counted in a liquid scintillation counter. One unit of
IL-I was defined as the amount of supernatant capable of doubling
the 3H-TdR incorporation by stimulated thymocytes.
IL-6 assay. The assay was performed as described previously.’6
Five thousand B13.29 cells per well were cultured for 48 hours in
flat-bottom microtiter plates in 200 iL Iscove’s modified Dulbecco’s
medium (IMDM) supplemented with 50 zmol/L 2-mercaptoetha-
nol, 5% FCS, 100 U/mL penicillin, and 100 zg/mL streptomycin
with or without twofold dilutions of the samples to be tested or of a
standard preparation containing 4,000 U/mL. Cells were pulsed for
the last six hours with 3H-TdR 0.2 MCi/well, and the uptake was
determined by liquid scintillation counting. One U/mL is the
concentration that yields half-maximal 3H-TdR incorporation in the
assay.
TNF/LT assay. The assay was performed as described by
Colotta et al.’7 WEHI 164 sarcoma cells (a gift from Dr A.
Mantovani, Istituto di Ricerche Farmacologiche “Mario Negri,”
Milan), 0.5 to 1.0 x 106/mL, were incubated in CM-FCS at 37#{176}C
with 1 zg/mL actinomycin D (Sigma) for three hours, washed
extensively, resuspended in CM-FCS, and labeled with 51Cr, as
described previou5ly’5; 5 x l0 cells/well were incubated for six
hours in triplicate with or without serial dilutions of test superna-
tants or with serial dilutions of hrTNF or hrLT to determine a
standard curve. At the end of the incubation period, aliquots of cells
were lysed in 0.1 N HCI to determine maximal lysis, 80 L were
harvested from each well, and radioactivity was detected in a liquid
scintillation counter. Specific lysis was determined according to the
following formula: Percentage of specific lysis - [(Exp - Sp)/
(Max - Sp)] x 100, where Exp is radioactivity release induced by
test supernatants, Sp is radioactivity spontaneously released by
labeled cells, and Max is radioactivity released by HCI-treated cells.
Distinction between the two cytokines was obtained with monospe-
cific antibodies.
OAF assay. The fetal rat long bone assay was performed as
described by Dewhirst et al.4 Pregnant rats were injected with 200
tCi 45Ca (NEN, Dupont Italia, Florence) on the 18th day of
gestation. Bone shafts of radii and ulnae were microdissected from
19-day fetuses and cultured in 0.5 mL BGJb medium (GIBCO,
Mascia Brunelli, Milan) containing I mg/mL bovine serum albumin
(BSA, Sigma) for one day to reduce exchangeable 45Ca. One bone
(radius or ulna) was then incubated in medium containing a diluted
test supernatant, and the controlateral bone was cultured in medium
alone as control. In some experiments, anti-IL-l-a and IL-I-fl, or
anti-TNF antibodies, at a final dilution of 1:100, or anti-LI antibod-
ies at a final dilution of 1 jg/mL, were added. Five pairs of bones
were used for each dilution. Bones were cultured for two days, media
were replaced, and the cultures were continued for three more days.
The percentage of45Ca released from a bone into the medium during
the entire culture was determined by measuring the radioactivity in
medium 1 , medium 2, and the trichloroacetic acid (ICA)-
solubilized bone by a liquid scintillation counter. OAF-induced
resorption was expressed as the difference between treated and
control percentages of 45Ca released during the culture. Maximal
resorption was determined by using 200 ng/mL parathyroid hor-
mone. For each group of five pairs, the mean and SE were
calculated. Significance was determined by a two-tailed Student’s
test.
RNA isolation and blot hybridization. The procedures used
were essentially those described by Maniatis et al.’8 Cells were lysed
in 4 mol/L guanidinium isothiocyanate, layered over 5.7 mol/L
cesium chloride, and centrifuged at 100,000 g at 20#{176}Cfor 18 hours.
The RNA pellets were recovered and precipitated with ethanol.
Aliquots of 2.0, 1.0, and 0.5 ig RNA (measured by spectrophotome-
try and ethidium bromide staining of test minigels) were slot-blotted
to a synthetic nylon transfer membrane (Gene Screen Plus, Dupont
Italia) using lOx standard saline citrate (SSC) (I x SSC = 150
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mmol/L NaCl, 15 mmol/L citrate, pH 7.0). Membranes were
prehybridized at 60#{176}Cin 1% sodium dodecyl sulfate (SDS), 1 mol/L
NaCI, 10% dextran sulfate, then hybridized in the same solution to
which 100 g/mL salmon sperm DNA and I x 106 cpm/mL
32P-labeled probe were added. Membranes were washed in 2 x SSC
for ten minutes, 2 x SSC/l% SDS for one hour at 60#{176}C,and 0.1 x
SSC for one hour at room temperature. After drying, membranes
were exposed to x-ray film with intensifying screens. DNA probes
were labeled to a specific activity of  l0 cpm/g with hexanucleo-
tide primers and 32PdCTP, as described previously.’9
RESULTS
Production of cytokines by plasma cells from MG
patients. Plasma cells were isolated from BM specimens of
12 patients with MM and nine patients with MGUS and
tested for production of factors with IL-i and TNF/LT
activity. Cells were cultured for 48 hours with or without
activation stimuli such as LPS, PHA, and hrIFN--y. Table I
shows that a clear-cut difference exists between the two types
of plasma cell populations. All MM plasma cell culture
supernatants contained large amounts of IL-l activity, not
increased by stimulation in culture. In contrast, supernatants
of plasma cells from MGUS patients consistently failed to
display IL-l activity, in either unstimulated or stimulated
cultures. When tested against WEHI 164 cells, neither MM
nor MGUS plasma cell supernatants from unstimulated or
stimulated cultures showed a significant cytotoxic activity, a
finding which suggests that TNF or LT was not released by
the malignant cells. The only exception was MM case 9, in
which plasma cells spontaneously released TNF/LT activity
in the supernatants (Table I). This activity was entirely
neutralized by monospecific anti-TNF antibodies (data not
shown). To rule out that the presence of inhibitors of TNF or
LT could interfere with the biologic assay, known amounts of
both cytokines were added to some supernatants which were
subsequently reassayed. The same amounts of TNF and LT
added were detected within the supernatants (Table 1).
IL-I can be produced by a variety of cell types, including
monocytes/macrophages, granulocytes, and possibly imma-
ture myeloid cell precursors.#{176} To ascertain whether the IL-I
detected in the above supernatants was actually produced by
plasma cells and not by other contaminating cell types,
unfractionated MM BM samples and purified plasma cell
suspensions thereof were cultured in parallel and superna-
tants were assayed for IL-l activity as described above.
Table 2 shows that in the single cases purified plasma cells
invariably released higher amounts of IL-i in comparison to
unfractionated BM cells. Coculture experiments with graded
numbers of autologous PB monocytes or granulocytes
yielded results consistent with the above data, since the
highest IL-I activity was detected within the supernatants of
purified plasma cell suspensions (Table 2).
T able 1 . C ytokine Producti on by Plasma Cells From MG Patients
TNF/LT Activity
IL- 1 Activity TNF/LT Activity Specific Cytotoxicity (%)
(U/mL) Specific Cytotoxicity (%) Cultured WIth
hrTNF, hilTSupernatants Unstimulated Stimulatedt Unstimulated Stimulatedt
From MM plasma cells
1 212 239 2.2 4.4 36.5 38.5
2 195 183 3.1 4.8 32.3 37.4
3 318 345 1.0 1.8 34.2 35.0
4 158 185 0.7 1.5 35.6 35.3
5 244 233 2.1 3.4 31.4 32.8
6 133 121 3.2 4.5 37.1 38.1
7 118 147 1.5 2.3 ND ND
8 85 89 1.4 2.8 ND ND
9 189 197 11.7 13.7 ND ND
10 225 215 2.0 2.1 ND ND
11 157 171 4.8 6.1 ND ND
12 284 275 0.6 1.3 35.8 36.7
From MGUS plasma cells
1 <10 <10 0.8 1.5 36.9 37.2
2 <10 <10 1.5 2.4 35.8 36.4
3 <10 <10 1.9 3.2 37.8 36.5
4 <10 <10 2.1 4.1 ND ND
5 <10 <10 3.1 3.8 ND ND
6 <10 <10 2.1 2.7 ND ND
7 <10 <10 1.1 1.8 ND ND
8 <10 <10 0.5 1.2 ND ND
9 <10 <10 0.8 1.4 ND ND
Plasma cells 1 x 106 isolated by rosetting techniques were cultured for 48 hours with or without stimulants; the supernatants were recovered and
tested for IL-i activity in the thymocyte costimulation assay using hrIL-1/3 as standard and for TNF/LT activity in the WEHI 1 64 cell cytotoxicity assay
using hrTNF ‘ hrLT as standard. Results are the mean of triplicate determinations. SD was consistently < i 0%.
The same LPS-stimulated supernatants were assayed with or without 5 U/mL hrTNF or hrLT. These amounts of hrTNF and hrLT in the standard
curves yielded 35.8% ± 4.2% and 36.9% ± 3.3% specific cytotoxicity, respectively.
tCells were cultured with LPS, 10 zg/mL, PHA, 1 zg/mL, or hrlFN-y, 2,000 U/mL.
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Sup 1 Sup 3
Table 2. IL-i Production by Unfractionated BM Cells
or Purified Plasma Cells From MM Patients
IL- 1 Production (U/mL) by Cells Fro m Patient’
Supernatants 7 10 1 1 12
FromBMMNC 72 i80 85 2i3
From purified plasma 1 28 230 i 57 284
cells
From purified plasma cells + autologous monocytes
1:0.5 96 i78 131 224
i:i 75 135 95 171
1:2 45 74 51 84
From purified plasma cells + autologous granulocytes
1:0.5 110 191 175 234
1:1 81 141 124 180
1:2 48 68 81 92
BM mononuclear cells (MNCs), obtained through F-H centrifugation,
were cultured for 48 hours in parallel with purified plasma cells and
purified plasma cells contaminated with autologous monocytes a’ granu-
locytes at the indicated ratios. The final cell number in each culture was
1 x 1 06. Supernatants were recovered and tested for IL- 1 activity.
Percentage of plasma cells in MNC suspensions was as follows:
patient 7, 51%; patient 10, 73%; patient 1 1, 48%; and patient 12,
78%.
To rule out that the IL-l detected in culture supernatants
could have been taken up by plasma cells in vivo and
subsequently released in vitro, purified MM plasma cells
were pulsed for six hours with cyc, washed, and cultured for
48 hours more. Table 3 shows that culture supernatants of
cyc-pretreated plasma cells showed markedly reduced IL-l
activity. The same supernatants, however, did not affect the
thymocyte proliferative response induced by addition of
exogenous IL-I (data not shown). This finding rules out that
some cyc had been carried over in the biologic assay.
To characterize the molecules produced by the malignant
cells further, IL-I activity was assayed with polyclonal
antibodies monospecific for IL-I-a and IL-l-fl. Figure 1
shows that addition of anti-IL-I-fl caused a >80% decrease
in the thymocyte proliferation induced by IL-I-rich superna-
tants, whereas anti-IL-I-a antibodies caused only a modest
decrease. Addition of both antibodies, however, failed to
abolish completely the IL-I activity of the supernatants.
Since lL-6 [interferon-fl2 (IFN-fl2), B-cell stimulatory fac-
Fig 1 . Effect of anti-IL-i -a and anti-IL-i -
antibodies on IL-i activity of MM plasma cell
supernatants. MM cell supernatants were tested
untreated (0) and treated with anti-IL-i-a (s),
anti-IL-i-fl (D). or both (s). at a final dilution of
1 :500. Results of three of seven experiments.
-a
E
C.,
Table 3. IL-i Activity in Supernatants From
Cycloheximide-Treated MM Plasma Cells
Supernatants
IL- 1 Prod uction (U/mL) by Plas
From Patient
ma cells
1 3 2 4
From unstimulated cells
From LPS-stimulated cells
From unstimulated
cyc-treated cells’
From LPS-stimulated
cyc-treated cells’
2 1 5
241
48
47
320 1 80
345 190
37 22
35 25
198
201
25
24
‘MM plasma cells were incubated with cyc 1 sg/mL for six hours,
washed extensively, and cultured at 1 x 108/mL for 48 hours with or
without LPS 1 0 g/mL. Supernatants were recovered and tested for IL-i
activity. In the same assay, controls with exogenous IL- i indicated that
no residual cyc was present.
tor-2, hybridoma/plasmacytoma growth factor, hepatocyte
stimulating factor] is active in the thymocyte comitogenic
assay,2’ culture supernatants of purified plasma cells from
five cases of M M were analyzed for the presence of this
cytokine. Table 4 shows that significant amounts of IL-6 in
two cases, and no cytokine at all in the remaining three, were
detected. Thus, a minor part of IL-I activity in some
supernatants of unstimulated cells could be related to an
effect of IL-6.
Production of cytokines by normal plasma cells. Nor-
mal B lymphocytes and Epstein-Barr virus (EBV)-trans-
formed lymphoblastoid B-cell lines produce both IL-i and
LT, either spontaneously or following in vitro activation.2224
Whether these functions are maintained during B-cell differ-
entiation is not known, however. To clarify this issue,
different cultures of tonsil or B PBLs were stimulated with
SAC, and the supernatants were recovered at various inter-
vals and tested for IL-I and TNF/LT activities. The time-
course analysis confirmed that resting B cells did not produce
detectable amounts of cytokines, and that significant IL-I
and TN F/LT activities were present in the supernatants of B
cells stimulated for 24, 48, and 72 hours (Fig 2). Experi-
ments performed in the presence of neutralizing antibodies
showed that 70% of cytotoxic activity against WEHI 164
cells was neutralized by anti-LT antibodies (data not
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Day of Culture
Table 4. IL-6 Production by Pla sma Cells From MM Patients
Supernatants of MM
Plasma Cells From Case lL-6 Activity (U/mL)
3 3.000
7 500
9 20
ii 3
12 10
Plasma cells from MM patients were cultured for 48 hours at 1 x
1 0’/mL. Supernatants were harvested and tested for lL-6 activity in the
B 1 3.29 hybridoma cell proliferation assay. A standard preparation
containing 4,000 U/mL IL-6 was used as positive control.
shown). Then the activities gradually decreased, and the
supernatants of cells cultured  I 20 hours were virtually
devoid of both IL-i and TNF/LT. As expected, the percent-
age of cIg cells in the same cultures gradually increased
from 1% to 5% on day 3 to 25% to 30% on day 8 (Fig 2).
Thus, differentiating B cells appear to lose progressively
their ability to produce cytokines. To assess more directly the
function of plasma cells, OKTi0 cells from stimulated
suspensions at day 8 were isolated and cultured for 48 hours
more, with or without various stimuli. In addition, since B
lymphocytes obtained from different tissues have been sug-
gested to differ in their functional properties,25 plasma cells
from BM specimens of cardiac surgery patients were isolated
and tested for their ability to release cytokines. Again, the
culture supernatants were devoid of both IL-l and TNF/LT
activities (data not shown), confirming that production of
these molecules is a property of activated B cells.
OAF activity in plasma cell culture supernatants. To
investigate whether and, perhaps more important, the extent
to which the plasma cell-derived IL-i could account for the
lytic bone lesions of MM, the OAF activity of purified
plasma cell supernatants from five cases of MM, two cases of
MGUS, and two normal donors were tested in a fetal rat long
bone assay, with or without neutralizing anti-IL-I, anti-
TNF, or anti-LT antibodies. All MM plasma cell superna-
tants induced a strong 45Ca release by cultured rat calvariae
(Fig 3). More important, the addition of anti-IL-i antibod-
ies caused reduction in the bone-resorbing activity, which
never reached the background levels, however. OAF activity
in the presence of LT- and TNF-specific antibodies was not
significantly affected (Fig 3). This finding is consistent with
the absence ofTNF/LT activity in plasma cell supernatants.
Expectedly, supernatants from purified MGUS or normal
donor plasma cells did not contain OAF activity (data not
shown).
Cytokine production by the RPM! 8226 myeloma cell
line. RPM! 8226 is a continuous cell line derived from the
PB of a patient with MM.26 This cell line could represent a
useful model for comparison with freshly isolated MM
plasma cells. We tested the culture supernatants of the
RPM! 8226 cell line for IL-i and TNF/LT activities. Table
5 shows that a high TNF/LT activity was detected and that
it could be blocked completely by anti-LT antibodies. On the
contrary, no iL-i activity was formed in the same superna-
tants. These results are therefore in contrast with those
obtained from analysis of MM plasma cell supernatants.
Cytokine-specific mRNA production by RPM! 8226 cells
and MM plasma cells. To determine whether the genes
encoding for TNF, LT, or IL-I were expressed in MM cells
and RPMI 8226 cells, total cellular mRNA from cells of
MM case 10 and from RPM! 8226 cells was analyzed by
slot-blot hybridization with DNA probes specific for IL-i-a,
IL-l-fl, TNF, and LT. Unexpectedly, the cells from the MM
case contained mRNA specific for TNF and LT, in addition
to that specific for IL-l-a and IL-i-fl (Fig 4). This result was
confirmed by the mRNA analysis of two additional MM
cases (cases 4 and 7, not shown). The mRNA from RPMI
8226 cells hybridized with LT- and TNF-specific, but not
with IL-l-a- or IL-l-fl-specific, DNA probes, as expected
(Fig 4).
DISCUSSION
Cytokines are a group of proteins endowed with powerful,
pleiotropic biologic properties. Although no definite evidence
for a critical role played by such proteins in the mechanisms
of disease has yet been provided,27 several studies have
suggested that inappropriate or excessive production of some
cytokines may be harmful.283#{176} Therefore, a fine control of
their biologic activities by specific or nonspecific inhibitors is
Fig 2. Time-course analysis of cytokine pro-
duction by normal tonsil B lymphocytes. B lympho-
cytes were cultured at 1 x i0/mL in CM-FCS
with SAC (1 :2.500 final dilution). Supernatants
were harvested daily and tested for IL-i activity in
the thymocyte costimulation assay and for TNF/
LT activity in the WEHI 1 64 cytotoxicity assay.
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Fig 3. Effect of anticytokine antibodies on
OAF activity of MM cell supernatants. MM cell
supernatants. untreated (U) or treated with anti-
IL-i-a and anti-IL-i-fl (0). with anti-IT (0). or
with anti-TNF (#{149}).were tested for OAF activity in
the fetal rat long bone assay. Results of one of five
representative experiments.
a biologically effective mechanism which could be eventually
used as therapeutic tool.
This study provides evidence that malignant plasma cells
from BM of MM patients produce IL-I in vitro. The purity
of the suspensions tested, confirmed also by lack of effect of
stimulants on cytokine release, together with the coculture
experiments with autologous normal cells, ruled out that cell
types other than myeloma plasma cells are responsible for
IL-l production. IL-l was actively synthesized in vitro by
MM plasma cells, in high amounts as compared with the
amount released by normal stimulated monocytic cells. Pro-
duction of IL-l was constitutive, and stimulation of the cells
in vitro did not produce further increase in IL-i release.
Finally, MM cell supernatants showed a strong OAF activity
in organ cultures, which was affected by monospecific anti-
IL-l antibodies. In contrast, plasma cells from MGUS
patients, normal marrow samples, or from stimulated blood
or tonsil B cell cultures did not release detectable amounts of
IL-I , even after stimulation. These results indicate that MM
plasma cells and MGUS plasma cells display distinctive
differences for some biologic features. The latter point could
be useful for differential diagnosis between MGUS and
low-mass MM. Low amounts of IL-6 were spontaneously
secreted by plasma cells from some cases of MM. They could
account for the minor residual IL-i activity detected in the
presence of neutralizing antibodies.
Stimulus
IL- 1 Activity
(U/mL)
Supernatants
Alone
Anti-IT
Antibodies
Nil <10 30 2.1
PHA <10 75 3.2
LPS <10 71 2.8
SAC <10 75 3.2
Cells 1 x i 0#{176}/mLwere cultured for 48 hours with or without
stimulants. The supernatants were recovered and tested for IL- 1 activity
in the thymocyte costimulation assay and for TNF/LT activity in the WEHI
1 64 cell cytotoxicity assay with or without anti-IT antibodies (1 ig/mL
final dilution). Results are the mean of triplicate determinations. SD was
consistently <10%.
With a single exception, TNF/LT activity was never
detectable in plasma cell culture supernatants. The presence
of inhibitors of TNF or LT was reasonably excluded by the
evidence that exogenous factors added to supernatants as
internal standards were entirely measured in the assay. The
WEHI 164 cell cytotoxicity assay is, in our experience,
capable of detecting as little as 50 pg/mL TNF/LT. Thus,
the possibility that lesser quantities were actually produced
cannot be dismissed. Consistent with this hypothesis is the
presence of TNF- and LT-specific mRNA in MM plasma
cells. An alternative explanation for the discrepancy between
the presence of mRNA and the absence of detectable TNF/
LT activity could be posttranscriptional events, affecting
translation, secretion, or both, as has been observed in other
systems.3’36
MM plasma cells produced mRNA for both the main
Fig 4. Slot-blot hybridization of mRNA extracted from MM
plasma cells (lanes 2, 4. 6. and 8) and from RPMI 8226 cells (lanes
1 , 3. 5, and 7) with DNA probes specific for IL-i-a (lanes 1 and 2),
IL-i - (lanes 3 and 4), TNF (lanes 5 and 6), and IT (lanes 7 and 8).
The amount of mRNA loaded onto each lane was checked by test
minigel.
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molecular species of IL- I , a and fi, and their culture superna-
tants contained both proteins. More than 80% of the IL-I
activity within the supernatants was accounted for by IL-i-fl,
which is about ten times more active than IL-l-a in inducing
osteoclast activation.5 The strong OAF activity exerted by
these supernatants in organ cultures was therefore expected,
as was the marked reduction in the presence of anti-IL-i
antibodies. However, OAF activity was not completely abol-
ished. Comparable results have been obtained in models
using continuous myeloma cell lines.37 Since the concentra-
tions of the antibodies were in great excess and always
capable of neutralizing the thymocyte costimulatory activity
of recombinant IL-I, we suggest that another factor or
factors could be responsible for the minor residual OAF
activity. The inefficacy of neutralizing antibodies against LT
or TNF in the OAF assay, together with the absence of
detectable cytotoxic activity against WEHI 164 cells in most
MM cell supernatants, suggests that these cytokines are not
responsible for the residual bone-resorbing activity. We
therefore conclude that IL-i is the major mediator of bone
resorption induced by BM MM cells.
Our observations concerning freshly isolated MM plasma
cells are in contrast with those of Garrett et al, who reported
recently that several continuous cell lines obtained from MM
patients produce abundant LT and do not release detectable
amounts of IL-i.37 We could confirm the above findings at
both the mRNA and protein levels, using the RPMI 8226
cell line. Nevertheless, BM cells, freshly isolated from mar-
row aspirates of MM patients, show inverse functional
properties. We believe that in vitro established cell lines do
not fully reproduce the behavior of malignant cells, which is
best assessed by studying malignant cells freshly obtained ex
vivo. Indeed, myeloma cell lines perhaps arise from and
hence are representative of the stem cell population,38’39
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